Henry J Kaminski

List of Publications by Year
in descending order

164	7,804	57758	60623
papers	citations	44 h-index	81 g-index

169	169	169	5917
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 2016, 375, 511-522.	27.0	695
2	Myasthenia gravis: past, present, and future. Journal of Clinical Investigation, 2006, 116, 2843-2854.	8.2	515
3	Spinal Epidural Abscess: A Ten-Year Perspective. Neurosurgery, 1990, 27, 177-184.	1.1	452
4	Myasthenia gravis: recommendations for clinical research standards11Reprinted with permission from Neurology 2000;55:16â€“23 (Â© AAN Enterprises, Inc.). Additional material related to this article can be found on the Neurology Web site at www.neurology.org. Consult the Table of Contents for the July 12 issue to find the title link for this article. See also Neurology 2000;55:3â€“4, 7â€“15.. Annals of Thoracic Surgery, 2000, 70, 327-334.	1.3	414
5	A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Human Molecular Genetics, 2002, 11, 263-272.	2.9	368
6	A Genome-Wide Association Study of Myasthenia Gravis. JAMA Neurology, 2015, 72, 396.	9.0	139
7	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
8	Comparative analysis of therapeutic options used for myasthenia gravis. Annals of Neurology, 2010, 68, 797-805.	5.3	135
9	Molecular architecture of the neuromuscular junction. Muscle and Nerve, 2006, 33, 445-461.	2.2	132
10	Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED]. Neurology, 2007, 68, 2144-2149.	1.1	132
11	Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis. JAMA Neurology, 2020, 77, 582.	9.0	126
12	Recommendations for myasthenia gravis clinical trials. Muscle and Nerve, 2012, 45, 909-917.	2.2	122
13	Why are eye muscles frequently involved in myasthenia gravis?. Neurology, 1990, 40, 1663-1663.	1.1	120
14	A genetic model for muscleâ€“eyeâ€“brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1). Mechanisms of Development, 2006, 123, 228-240.	1.7	115
15	Extraocular muscles are spared in advanced duchenne dystrophy. Annals of Neurology, 1992, 32, 586-588.	5.3	114
16	Pitx2 , an Atrial Fibrillation Predisposition Gene, Directly Regulates Ion Transport and Intercalated Disc Genes. Circulation: Cardiovascular Genetics, 2014, 7, 23-32.	5.1	103
17	Pathophysiology of Myasthenia Gravis. Seminars in Neurology, 2004, 24, 21-30.	1.4	98
18	Nitric oxide synthase is concentrated at the skeletal muscle endplate. Brain Research, 1996, 730, 238-242.	2.2	91

#	Article	IF	Citations
19	Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia. Archives of Neurology, 2000, 57, 527.	4.5	87
20	Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. Neuromuscular Disorders, 2003, 13, 223-235.	0.6	85
21	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurology, The, 2020, 19, 970-971.	10.2	85
22	Intracranial Suppuration. Neurosurgery, 1994, 34, 974-981.	1.1	83
23	Temporal and spatial mRNA expression patterns of TGF-Î²1, 2, 3 and TÎ²RI, II, III in skeletal muscles of mdx mice. Neuromuscular Disorders, 2006, 16, 32-38.	0.6	83
24	Novel complement inhibitor limits severity of experimentally myasthenia gravis. Annals of Neurology, 2009, 65, 67-75.	5.3	83
25	Anti-C5 Antibody Treatment Ameliorates Weakness in Experimentally Acquired Myasthenia Gravis. Journal of Immunology, 2007, 179, 8562-8567.	0.8	78
26	Status of the Thymectomy Trial for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone. Annals of the New York Academy of Sciences, 2008, 1132, 344-347.	3.8	69
27	Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. Journal of the Neurological Sciences, 2008, 264, 106-111.	0.6	69
28	Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Experimental Neurology, 2004, 189, 333-342.	4.1	68
29	Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Current Opinion in Neurology, 2008, 21, 8-15.	3.6	68
30	Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophicmdxmice. FASEB Journal, 2003, 17, 1-27.	0.5	66
31	Nitric oxide: biologic effects on muscle and role in muscle diseases. Neuromuscular Disorders, 2001, 11, 517-524.	0.6	64
32	Development of a Thymectomy Trial in Nonthymomatous Myasthenia Gravis Patients Receiving Immunosuppressive Therapy. Annals of the New York Academy of Sciences, 2003, 998, 473-480.	3.8	63
33	Disorders of neuromuscular junction ion channels11In collaboration with The American Physiological Society, Thomas E. Andreoli, MD, Editor. American Journal of Medicine, 1999, 106, 97-113.	1.5	62
34	Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. Journal of Clinical Investigation, 2002, 110, 1269-1274.	8.2	62
35	Extraocular Muscle Susceptibility to Myasthenia Gravis. Annals of the New York Academy of Sciences, 2008, 1132, 220-224.	3.8	61
36	Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. Journal of Clinical Investigation, 2002, 110, 1269-1274.	8.2	58

#	Article	IF	Citations
37	Differential Susceptibility of the Ocular Motor System to Disease. Annals of the New York Academy of Sciences, 2002, 956, 42-54.	3.8	57
38	Crossâ€sectional analysis of the Myasthenia Gravis Patient Registry: Disability and treatment. Muscle and Nerve, 2019, 60, 707-715.	2.2	56
39	Treatment of Myasthenia Gravis. Current Neurology and Neuroscience Reports, 2011, 11, 89-96.	4.2	55
40	Treatment of Ocular Myasthenia. Archives of Neurology, 2000, 57, 752.	4.5	54
41	Myeloid-Derived Suppressor Cells as a Potential Therapy for Experimental Autoimmune Myasthenia Gravis. Journal of Immunology, 2014, 193, 2127-2134.	0.8	54
42	Eye muscle sparing by the muscular dystrophies: Lessons to be learned?. Microscopy Research and Technique, 2000, 48, 192-203.	2.2	53
43	Ocular Myasthenia. Neurologic Clinics, 2018, 36, 241-251.	1.8	50
44	Susceptibility of Ocular Tissues to Autoimmune Diseases. Annals of the New York Academy of Sciences, 2003, 998, 362-374.	3.8	49
45	Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Experimental Neurology, 2006, 202, 287-293.	4.1	47
46	Ocular Myasthenia. Neurologist, 2006, 12, 231-239.	0.7	47
47	Myosin Heavy Chain Expression in Mouse Extraocular Muscle: More Complex Than Expected. , 2010, 51, 6355.		46
48	Distinctive morphological and gene/protein expression signatures during myogenesis in novel cell lines from extraocular and hindlimb muscle. Physiological Genomics, 2006, 24, 264-275.	2.3	41
49	Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurology, The, 2022, 21, 189-202.	10.2	41
50	Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients. Cytokine, 2016, 78, 44-46.	3.2	40
51	Advances in autoimmune myasthenia gravis management. Expert Review of Neurotherapeutics, 2018, 18, 573-588.	2.8	40
52	Acetylcholine receptor subunit gene expression in thymic tissue. Muscle and Nerve, 1993, 16, 1332-1337.	2.2	39
53	Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 2016, 375, 2005-2007.	27.0	39
54	Complement Inhibitor Therapy for Myasthenia Gravis. Frontiers in Immunology, 2020, 11, 917.	4.8	39

#	Article	IF	Citations
55	Implementing clinical trials on an international platform: Challenges and perspectives. Journal of the Neurological Sciences, 2012, 313, 1-6.	0.6	38
56	Molecular Organization of the Extraocular Muscle Neuromuscular Junction: Partial Conservation of and Divergence from the Skeletal Muscle Prototype. , 2003, 44, 1918.		37
57	Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Molecular Therapy - Methods and Clinical Development, 2019, 13, 484-492.	4.1	37
58	Transient neurologic deficit caused by chronic subdural hematoma. American Journal of Medicine, 1992, 92, 698-700.	1.5	36
59	Nitric oxide synthase in aging rat skeletal muscle. Mechanisms of Ageing and Development, 1999, 109, 177-189.	4.6	36
60	Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	36
61	ENDOCRINE NEUROMYOPATHIES. Neurologic Clinics, 1997, 15, 673-696.	1.8	35
62	Ocular muscle involvement by myasthenia gravis. Annals of Neurology, 1997, 41, 419-420.	5.3	35
63	Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Review of Clinical Immunology, 2008, 4, 43-52.	3.0	34
64	An Altered Phenotype in a Conditional Knockout of Pitx2 in Extraocular Muscle. , 2009, 50, 4531.		33
65	Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30649-30660.	7.1	33
66	The gamma-Subunit of the Acetylcholine Receptor Is Not Expressed in the Levator Palpebrae Superioris. Neurology, 1995, 45, 516-518.	1.1	32
67	T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis. Journal of Neuroimmunology, 2000, 108, 29-39.	2.3	31
68	Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registry. Muscle and Nerve, 2018, 58, 90-98.	2.2	31
69	Survivin as a Potential Mediator to Support Autoreactive Cell Survival in Myasthenia Gravis: A Human and Animal Model Study. PLoS ONE, 2014, 9, e102231.	2.5	31
70	Neuromuscular Manifestations of Endocrine Disorders. Neurologic Clinics, 2002, 20, 35-58.	1.8	29
71	Ocular myasthenia revisited: Insights from pseudo-internuclear ophthalmoplegia. Journal of Neurology, 2007, 254, 1569-1574.	3.6	28
72	The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial. Journal of Neuroimmunology, 2008, 201-202, 80-84.	2.3	28

#	Article	IF	Citations
73	Thymectomy for myasthenia gravis: evaluation requires controlled prospective studies. Annals of Thoracic Surgery, 2003, 76, 1-3.	1.3	27
74	Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis. Neurology, 2018, 91, e1365-e1367.	1.1	26
75	Electrodiagnostic approach to the patient with suspected neuromuscular junction disorder. Neurologic Clinics, 2002, 20, 557-586.	1.8	25
76	Pitx2 regulates myosin heavy chain isoform expression and multiâ€innervation in extraocular muscle. Journal of Physiology, 2011, 589, 4601-4614.	2.9	25
77	‹i›‹scp›GR‹/scp›‹/i› gene polymorphism is associated with interâ€subject variability in response to glucocorticoids in patients with myasthenia gravis. European Journal of Neurology, 2016, 23, 1372-1379.	3.3	25
78	Gender differences in prednisone adverse effects. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e507.	6.0	25
79	Gender differences in quality of life among patients with myasthenia gravis in China. Health and Quality of Life Outcomes, 2020, 18, 296.	2.4	25
80	Perimysial Fibroblasts of Extraocular Muscle, as Unique as the Muscle Fibers. , 2010, 51, 192.		24
81	Targeting therapy to the neuromuscular junction: Proof of concept. Muscle and Nerve, 2014, 49, 749-756.	2.2	24
82	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	2.2	24
83	Nitric oxide synthase expression and effects of nitric oxide modulation on contractility of rat extraocular muscle. FASEB Journal, 2001, 15, 1764-1770.	0.5	22
84	Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity. Cytokine, 2017, 96, 279-285.	3.2	22
85	Monoclonal Antibody-Based Therapies for Myasthenia Gravis. BioDrugs, 2020, 34, 557-566.	4.6	22
86	Spinal cord histopathology in long-term survivors of poliomyelitis. Muscle and Nerve, 1995, 18, 1208-1209.	2.2	21
87	Randomized trial of thymectomy in myasthenia gravis. Journal of Thoracic Disease, 2016, 8, E1782-E1783.	1.4	21
88	Genomic Profiling RevealsPitx2Controls Expression of Mature Extraocular Muscle Contractionâ€“Related Genes. , 2012, 53, 1821.		20
89	Biomarker development for myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1275, 101-106.	3.8	20
90	Ryanodine receptor gene expression thymomas. , 1998, 21, 1299-1303.		19

#	Article	IF	Citations
91	Outcome of plasmapheresis in myasthenia gravis: Delayed therapy is not favorable. Muscle and Nerve, 2011, 43, 578-584.	2.2	19
92	Acetylcholine Receptor Epitopes in Ocular Myastheniaa. Annals of the New York Academy of Sciences, 1998, 841, 309-319.	3.8	18
93	Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles. Annals of the New York Academy of Sciences, 2011, 1233, 26-33.	3.8	18
94	Two steps forward, one step back: Mycophenolate mofetil treatment for myasthenia gravis in the united states. Muscle and Nerve, 2015, 51, 635-637.	2.2	18
95	Mexiletine for Treatment of Myotonia. JAMA - Journal of the American Medical Association, 2012, 308, 1377.	7.4	17
96	Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle and Nerve, 2013, 47, 33-40.	2.2	17
97	Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology, 2020, 95, e755-e766.	1.1	17
98	The role of complement in experimental autoimmune myasthenia gravis. Annals of the New York Academy of Sciences, 2012, 1274, 127-132.	3.8	16
99	RNA Expression Analysis of Passive Transfer Myasthenia Supports Extraocular Muscle as a Unique Immunological Environment. , 2014, 55, 4348.		16
100	The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis. Frontiers in Neurology, 2017, 8, 230.	2.4	16
101	Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (<scp>MGâ€CE</scp>). Muscle and Nerve, 2021, 64, 270-276.	2.2	16
102	Neuromuscular transmission defect caused by carbamazepine1. , 1999, 22, 1293-1296.		15
103	Practice parameters and focusing research: Plasma exchange for myasthenia gravis. Muscle and Nerve, 2011, 43, 625-626.	2.2	15
104	Importance and hurdles to drug discovery for neurological disease. Annals of Neurology, 2013, 74, 441-446.	5.3	15
105	Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study. Muscle and Nerve, 2020, 62, 261-266.	2.2	15
106	Heme oxygenase-2 expression at rat neuromuscular junctions. Neuroscience Letters, 1999, 273, 143-146.	2.1	14
107	Seronegative Myasthenia Gravisâ€"A Vanishing Disorder?. JAMA Neurology, 2016, 73, 1055.	9.0	14
108	Adverse effects of myasthenia gravis on rat phrenic diaphragm contractile performance. Journal of Applied Physiology, 2004, 97, 895-901.	2.5	13

#	Article	IF	Citations
109	Protective effect of scFvâ€ÐAF fusion protein on the complement attack to acetylcholine receptor: A possible option for treatment of myasthenia gravis. Muscle and Nerve, 2012, 45, 668-675.	2.2	13
110	Acetylcholine receptor antibodyâ€“mediated animal models of myasthenia gravis and the role of complement. Annals of the New York Academy of Sciences, 2018, 1413, 136-142.	3.8	13
111	MicroRNA and mRNA expression associated with ectopic germinal centers in thymus of myasthenia gravis. PLoS ONE, 2018, 13, e0205464.	2.5	13
112	Serum Metabolomic Response of Myasthenia Gravis Patients to Chronic Prednisone Treatment. PLoS ONE, 2014, 9, e102635.	2.5	13
113	Central nervous system complications of cystosarcoma phyllodes. Cancer, 1993, 72, 126-130.	4.1	12
114	Thymectomy for myasthenia gravis in older patients. Journal of the American College of Surgeons, 2001, 193, 340-341.	0.5	12
115	Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open, 2020, 10, e037909.	1.9	12
116	Congenital Disorders of Neuromuscular Transmission. Hospital Practice (1995), 1992, 27, 73-85.	1.0	11
117	Inpatient cost analysis for treatment of myasthenia gravis. Muscle and Nerve, 2017, 56, 1114-1118.	2.2	11
118	The Myasthenic Syndromes. , 1996, , 565-593.		11
119	Natural History of Myasthenia Gravis. , 2012, , 90-107.		11
120	Monocular visual deprivation in macaque monkeys: a profile in the gene expression of lateral geniculate nucleus by laser capture microdissection. Molecular Vision, 2008, 14, 1401-13.	1.1	11
121	Ocular flutter and ataxia associated with AIDS-related complex. Neuro-Ophthalmology, 1991, 11, 163-167.	1.0	10
122	Preoperative preparation of patients with myasthenia gravis forestalls postoperative respiratory complications after thymectomy. Annals of Thoracic Surgery, 2003, 75, 1068.	1.3	10
123	Problems in the evaluation of thymectomy for myasthenia gravis. Annals of Thoracic Surgery, 2002, 73, 1027-1028.	1.3	9
124	How clinical trials of myasthenia gravis can inform pre-clinical drug development. Experimental Neurology, 2015, 270, 78-81.	4.1	9
125	Thymectomy is safe for myasthenia gravis patients: Analysis of the NSQIP database. Muscle and Nerve, 2016, 53, 370-374.	2.2	9
126	Corticosteroid Treatment-Resistance in Myasthenia Gravis. Frontiers in Neurology, 2022, 13, 886625.	2.4	9

#	Article	IF	Citations
127	Autoantibody Testing in Neuromuscular Disorders, Part II. Journal of Clinical Neuromuscular Disease, 2000, 2, 96-105.	0.7	8
128	Extraocular Muscle Fatigue. Annals of the New York Academy of Sciences, 2002, 956, 397-398.	3.8	8
129	Treatment of Myasthenia Gravis. , 2003, , 197-221.		8
130	Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet Journal of Rare Diseases, 2021, 16, 457.	2.7	8
131	Treatment of the Elderly Patient with Headache or Trigeminal Neuralgia. Drugs and Aging, 1991, 1, 48-56.	2.7	7
132	Insights into Possible Skeletal Muscle Nicotinic Acetylcholine Receptor (AChR) Changes in Some Congenital Myasthenias from Physiological Studies, Point Mutations, and Subunit Substitutions of the AChR. Annals of the New York Academy of Sciences, 1993, 681, 435-450.	3.8	7
133	Nitric oxide myotoxicity is age related. Mechanisms of Ageing and Development, 2000, 113, 183-191.	4.6	7
134	The preferential involvement of extraocular muscles by myasthenia gravis. Neuro-Ophthalmology, 2001, 25, 219-228.	1.0	7
135	Differential RNA Expression Profile of Skeletal Muscle Induced by Experimental Autoimmune Myasthenia Gravis in Rats. Frontiers in Physiology, 2016, 7, 524.	2.8	7
136	Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution. PLoS ONE, 2018, 13, e0197435.	2.5	7
137	A Neurologistâ€™s Perspective on Understanding Myasthenia Gravis. Thoracic Surgery Clinics, 2019, 29, 133-141.	1.0	6
138	Pathological Analysis of Spinal Cords from Survivors of Poliomyelitis. Annals of the New York Academy of Sciences, 1995, 753, 390-393.	3.8	5
139	Neuromuscular junction as Achilles' heel: Yet another autoantibody?. Neurology, 2014, 82, 1942-1943.	1.1	5
140	Concurrent Paraspinous Myopathy and Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 2017, 18, 218-222.	0.7	5
141	Clinical trials for myasthenia gravis: a historical perspective. Annals of the New York Academy of Sciences, 2018, 1413, 5-10.	3.8	5
142	Epstein-barr virus: Trigger for autoimmunity?. Annals of Neurology, 2010, 67, NA-NA.	5.3	4
143	Editorial: Special issue on standardization of preclinical evaluation of animal models for myasthenia gravis. Experimental Neurology, 2015, 270, 1-2.	4.1	4
144	Treatment of Myasthenia Gravis. , 2018, , 169-187.		4

#	Article	IF	Citations
145	Relation of Aphemia and Agraphia. European Neurology, 1992, 32, 302-304.	1.4	3
146	Shortage of generic neurologic therapeutics. Neurology, 2017, 89, 2431-2437.	1.1	3
147	The Presence of Survivin on B Cells from Myasthenia Gravis Patients and the Potential of an Antibody to a Modified Survivin Peptide to Alleviate Weakness in an Animal Model. Journal of Immunology, 2020, 205, 1743-1751.	0.8	3
148	Impact of the Covid-19 epidemic on a US sample of patients with myasthenia gravis. Therapeutic Advances in Rare Disease, 2022, 3, 263300402210826.	0.7	3
149	Nitric Oxide and cGMP Modulation of Extraocular Muscle Contraction. Annals of the New York Academy of Sciences, 2002, 956, 399-400.	3.8	2
150	Reduced plasmablast frequency is associated with seronegative myasthenia gravis. Muscle and Nerve, 2021, 63, 577-585.	2.2	2
151	SECTION OF GEOLOGY AND MINERALOGY: DEVELOPMENT OF THE U.S. NAVY'S ICE FORECASTING SERVICE, 1947â€“1953, AND ITS GEOLOGICAL IMPLICATIONS*. Transactions of the New York Academy of Sciences, 1954, 16, 162-174.	0.2	1
152	Congenital Neuromuscular Diseases Presenting in Adulthood. Seminars in Neurology, 1996, 16, 47-54.	1.4	1
153	Erratum to â€œThe MGTX experience: Challenges in planning and executing an international, multicenter clinical trialâ€•[J. Neuroimmunol. 201â€“202(2008)80â€“84]. Journal of Neuroimmunology, 2009, 217, 103.	2.3	1
154	Treatment of Myasthenia Gravis. , 2009, , 157-173.		1
155	MYF-4 Does Not Mediate AChR Receptor Subunit mRNA Expression in Thymic Tissues. Annals of the New York Academy of Sciences, 1993, 681, 103-106.	3.8	0
156	Autoantibody Testing in Neuromuscular Disorders, Part I. Journal of Clinical Neuromuscular Disease, 2000, 2, 84-95.	0.7	0
157	The third leg of neurology training. Neurology, 2014, 83, 1778-1779.	1.1	0
158	Rare disease levels of evidence. Neurology, 2017, 89, 988-989.	1.1	0
159	Emerging Therapeutics for Myasthenia Gravis. , 2018, , 319-333.		0
160	Clinical Trial Design for Myasthenia Gravis. , 2018, , 335-344.		0
161	Myasthenia Gravis: An Illustrated History. Archives of Neurology, 2003, 60, 1487.	4.5	0
162	C5 complement inhibition contributes to increased proliferative activity and antigen specific recall response in experimentally acquired myasthenia gravis (EAMG). FASEB Journal, 2008, 22, 1074.10.	0.5	0

#	Article	IF	Citations
163	Autoantibody Testing of Autoimmune Neuromuscular Junction, Hyperexcitability, and Muscle Disorders. , 2014, , 69-77.		0
164	Cognitive-Behavioral Therapy for Psychiatric Comorbidity in a Case of Muscle-Specific Kinaseâ€“Positive Myasthenia Gravis. primary care companion for CNS disorders, The, 2017, 19, .	0.6	0